MP49-05 PROGNOSTIC IMPACT OF C-REACTIVE PROTEIN KINETICS ON SURVIVAL OF PATIENTS WITH ADVANCED UROTHELIAL CARCINOMA

Abstract

You have accessJournal of UrologyBladder Cancer: Invasive III1 Apr 2016MP49-05 PROGNOSTIC IMPACT OF C-REACTIVE PROTEIN KINETICS ON SURVIVAL OF PATIENTS WITH ADVANCED UROTHELIAL CARCINOMA Junichiro Ishioka, Kazutaka Saito, Masaharu Inoue, Masaya Itoh, Soichiro Yoshida, Minato Yokoyama, Yoh Matsuoka, Noboru Numao, Yasuhisa Fujii, and Kazunori Kihara Junichiro IshiokaJunichiro Ishioka More articles by this author , Kazutaka SaitoKazutaka Saito More articles by this author , Masaharu InoueMasaharu Inoue More articles by this author , Masaya ItohMasaya Itoh More articles by this author , Soichiro YoshidaSoichiro Yoshida More articles by this author , Minato YokoyamaMinato Yokoyama More articles by this author , Yoh MatsuokaYoh Matsuoka More articles by this author , Noboru NumaoNoboru Numao More articles by this author , Yasuhisa FujiiYasuhisa Fujii More articles by this author , and Kazunori KiharaKazunori Kihara More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.418AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Pretreatment C-reactive protein (CRP) levels are prognostic for various stages of urothelial carcinoma. To demonstrate that dynamic changes in serum CRP would be a useful biomarker for advanced urothelial carcinoma (aUC), we evaluated the impact of CRP kinetics on patient survival. METHODS Two hundred twenty three patients with aUC were treated from 1995 to 2011, with a median follow-up period of 5.1 months (interquartile range: 2.1 to 12 months). Overall, 138 patients underwent multimodal therapeutic intervention. Patients were divided into three groups according to CRP kinetics of the baseline nadir model. Patients whose pretreatment CRP levels were <5 mg/l; patients whose pretreatment CRP levels were >5 mg/l and normalized (<5 mg/l) at least one time during treatment; and patients whose pretreatment CRP levels were >5 mg/l and never normalized were assigned to the non-elevated, normalized and non-normalized CRP group, respectively. The prognostic impact of CRP kinetics was determined. RESULTS In 76 of the 138 patients (55%), CRP levels were elevated at the aUC diagnosis. During treatment, CRP levels normalized in 17 of 76 patients within 2 months, and remained elevated in the remaining 59 patients (43%). Objective responses for first-line therapies were obtained in 37%, 24% and 7% for non-elevated, normalized and non-normalized CRP groups. Overall survival rates were significantly different between non-elevated, normalized and non-normalized CRP groups (p < 0.001), with a 1-yr survival rate of 71%, 41% and 11%, respectively. In multivariate analysis, CRP kinetics was an independent significant prognostic factor for overall survival. Furthermore, in patients with progressive disease after administration of first-line therapies, their 1-year survival rate was clearly stratified according to CRP kinetics. CONCLUSIONS CRP kinetics can be a novel, widely available biomarker for patients with advanced urothelial carcinoma. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e665-e666 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Junichiro Ishioka More articles by this author Kazutaka Saito More articles by this author Masaharu Inoue More articles by this author Masaya Itoh More articles by this author Soichiro Yoshida More articles by this author Minato Yokoyama More articles by this author Yoh Matsuoka More articles by this author Noboru Numao More articles by this author Yasuhisa Fujii More articles by this author Kazunori Kihara More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...